Enrollment in This Study Is Complete
Post-Market Registry of Auryon Atherectomy System in Subjects Affected with Infrainguinal Peripheral Artery Disease
The PATHFINDER Post-Market Registry was a multi-center, prospective, observational registry that collected data on patients with symptomatic Peripheral Artery Disease (PAD) who underwent atherectomy with the Auryon System.
The Auryon Atherectomy System is a proprietary solid-state laser technology platform that is FDA-indicated for use in the treatment, including atherectomy, of infrainguinal stenoses and occlusions, including in-stent restenosis. The Auryon System utilizes a solid-state 355nm, short-pulse laser that is safe and effective in the treatment for infrainguinal atherosclerosis (above and below the knee) in multiple lesion types and calcification levels while preserving the integrity of endothelial wall of the vessel.
Please contact a representative to learn more.
If you would like to learn more about the PATHFINDER Post-Market Registry, please email medicalaffairs@angiodynamics.com.
GENERAL NOTE: B-Laser was the initial name of the device. In 2020, the name “B-Laser” was replaced by the Auryon Atherectomy System. Both names (B-Laser and the Auryon Atherectomy System, also referred to simply as “Auryon”) refer to the same device. All references for B-Laser on this website, supporting documents including publications and on the device labeling for this study, refer to the Auryon Atherectomy System.
Auryon, and B-Laser are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are property of their respective owners.
